Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 3 to 6

Folinic acid vs placebo in young children with autism

Official title: A Placebo-Controlled, Randomized, Double-Blind Study to Assess the Safety, Tolerability and Efficacy of Folinic Acid Administered to Pediatric Subjects With Autism Spectrum Disorder (ASD)

Run by Shaare Zedek Medical Center · NCT07642661 · Data updated 2026-11-12

This trial tests whether folinic acid can help improve communication and behavior in children with autism aged 3 to 6 years who have not been diagnosed with a known genetic syndrome.

More Autism Spectrum Disorder trials

Quick facts

PhasePhase 2
Study typeInterventional
Ages3 Years to 6 Years
SexAll
Enrollment150 (estimated)
SponsorShaare Zedek Medical Center
Academic / other
Drugs / interventionsmethotrexate
Locations1 site (Jerusalem, N/A = Not Applicable)
StatusRecruiting
StartedJune 23, 2026
Main results expectedDecember 31, 2027
Study endsDecember 31, 2027
Registry record updatedJune 22, 2026
Trial IDNCT07642661 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are children ages 3-6 with non-syndromic ASD, a confirmed diagnosis, and moderate symptom severity who meet weight and clinical criteria.

Probably not a fit

Children with comorbid conditions, recent seizure activity, or prior folinic acid exposure may be less likely to benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 2, randomized, placebo-controlled study evaluating folinic acid in children with autism spectrum disorder. Eligible participants are 3 to 6 years old with a DSM-5 ASD diagnosis confirmed by ADOS-2, who are non-syndromic and meet certain severity criteria. Participants are assigned to receive either folinic acid or placebo to determine its effects on core and associated symptoms. Outcomes focus on communication, social functioning, and behavior, with careful monitoring for safety and tolerability. The study is led by Prof. Adi Aran and conducted at Shaare Zedek Medical Center in Jerusalem.

Why it matters

Potential benefit: If successful, children may show improved communication and social skills, with potential reductions in behavioral symptoms.

How similar studies have gone: Prior small studies suggested possible benefits of folinic acid in ASD but evidence is not yet conclusive, making this a somewhat novel but exploratory trial.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Children aged 3 to 6 years.
* Diagnosis of autism spectrum disorder (ASD) according to DSM-5 criteria.
* ASD diagnosis confirmed by Autism Diagnostic Observation Schedule, Second Edition (ADOS-2).
* ASD diagnosis made at least 6 months before screening.
* Non-syndromic ASD, defined as ASD occurring in the absence of a known genetic syndrome, chromosomal abnormality, major congenital anomaly, or identifiable metabolic or neurological disorder.
* CGI-S score ≥ 4.
* ABC-I score ≥ 12.
* SRS-2 total T-score ≥ 66.
* Body weight between 11.45 kg and \<27 kg.

Exclusion Criteria:

* A seizure or a change in antiepileptic medication within 8 weeks prior to randomization.
* Clinically significant abnormalities on physical examination or laboratory testing, including significant impairment of cardiac, hepatic, or renal function.
* Treatment with folinic acid within 3 months prior to randomization.
* Any change in pharmacological treatment, behavioral treatment, home environment, or school setting (other than school holidays) within 4 weeks prior to randomization, or planned changes during study participation.
* Predicted inability or unwillingness to comply with study procedures.
* Use of antifolate medications or other agents known to interfere with folate metabolism (e.g., methotrexate, trimethoprim).

Where it's running

  • Shaare Zedek Medical Center
    Jerusalem, N/A = Not Applicable, Israel
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.